Chimeric antigen receptor therapies: Development, design, and implementation
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2025.04.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Madeline J Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, Minn. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Killer Cells, Natural, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIH NCI.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T and natural killer (NK) cell therapies represent a promising strategy for the treatment of cancers and other chronic diseases. Engineered CAR constructs endow immune cells with the ability to target desired antigens with high specificity, allowing for directed responses to antigen-expressing cells. CAR T and NK cells have shown marked success in the treatment of hematologic malignancies, although there remains a large population of patients with disease that fails to respond to CAR therapies, and their efficacy in solid tumors is still limited. In this review, we provide a broad overview of the development, design, and implementation of CAR therapies from bench to bedside. We discuss the building blocks of CAR constructs and how these can be manipulated to optimize CAR functionality, review the possible sources of T and NK cells for CAR therapies, and examine the limitations of both CAR T and CAR NK cells. Finally, we discuss recent breakthroughs in the CAR field and consider how these advances may affect the success of CAR therapies in the years to come.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota, Minneapolis, Minn.
- Department of Medicine, University of Minnesota, Minneapolis, Minn. Electronic address: mille011@umn.edu.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIH NCI
- NIH
Zitieren
APA
Lee, M. J., Cichocki, F., & Miller, J. S. (2025). Chimeric antigen receptor therapies: Development, design, and implementation. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.04.005
Vancouver
Lee MJ, Cichocki F, Miller JS. Chimeric antigen receptor therapies: Development, design, and implementation. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.04.005
BibTeX
@article{Lee2025,
author = {Lee, Madeline J and Cichocki, Frank and Miller, Jeffrey S},
title = {Chimeric antigen receptor therapies: Development, design, and implementation},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2025.04.005}
}
EUVIMED